{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:06:26Z","timestamp":1762506386683},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vismodegib is a novel hedgehog pathway inhibitor approved to treat advanced and metastatic basal cell carcinoma (<jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>) in the United States. Several studies have demonstrated efficacy for treatment of new and existing <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content> in both basal cell nevus syndrome (<jats:styled-content style=\"fixed-case\">BCNS<\/jats:styled-content>) and non\u2010<jats:styled-content style=\"fixed-case\">BCNS<\/jats:styled-content> patients. However, severe and numerous adverse events are associated with vismodegib use. Therefore, we have also examined all of the currently published clinical trials and tabulated the available adverse events for review. The most frequently reported adverse events include muscle spasms (53.4%), dysgeusia\/ageusia (49.3%), alopecia (38.8%), fatigue (32.0%), nausea (28.4%), weight loss (24.2%), and decreased appetite (16.5%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Study<\/jats:title><jats:p>We report a case of a previously healthy 72\u2010year\u2010old male with a history of innumerable <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>s who developed severe nausea, jaundice, and cholestasis with significantly elevated <jats:styled-content style=\"fixed-case\">BUN<\/jats:styled-content>, creatinine, and liver enzymes one\u00a0month after starting vismodegib. The patient began using over\u2010the\u2010counter nonsteroidal anti\u2010inflammatory drugs (<jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s) to treat severe, vismodegib\u2010induced myalgia. No other new medications were started. Our patient had no history of liver disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Herein, we describe a potential serious adverse effect associated with vismodegib use. Whether the illness is directly attributable to the medication or the result of drug\u2010drug interactions between vismodegib and <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s, practitioners should be aware of the possibility of hepatic injury in patients on vismodegib. Furthermore, patients need to be informed of the potential risks of vismodegib and should be monitored closely to ensure that life\u2010threatening complications of treatment are avoided.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.12543","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T08:17:48Z","timestamp":1405066668000},"page":"370-374","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety"],"prefix":"10.1111","volume":"54","author":[{"given":"Mark M.","family":"Ash","sequence":"first","affiliation":[{"name":"Department of Dermatology University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet S.","family":"Jolly","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2006.12.011"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-32"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33139"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.08.049"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0568"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905360"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113713"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113538"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1796"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1996-6"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0972"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3829"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2745"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1800"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2012.02513.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.6.673"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021844"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-12-200212170-00007"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04171.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)85085-4"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.01.039"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050706"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199304000-00029"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(03)00022-9"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535340-000000000-00000"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(11)60093-3"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00777-3"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02092.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7405.18"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.12543","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.12543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:21:09Z","timestamp":1696306869000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.12543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/ijd.12543"],"URL":"https:\/\/doi.org\/10.1111\/ijd.12543","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]},"assertion":[{"value":"2014-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}